Table 1.
Significantly changed proteins in AD patients treated with acitretin
| Protein name | Gene name | (Aci./Pla.) | P‐value | Reference ADAM10 substrate |
|---|---|---|---|---|
| Decrease | ||||
| Basal cell adhesion molecule | BCAM | 0.79 | 0.0116 | Cai et al ( 2016) |
| Beta‐1,4‐galactosyltransferase 1 | B4GALT1 | 0.66 | 0.0144 | |
| Beta‐galactoside alpha‐2,6‐sialyltransferase 2 | ST6GAL2 | 0.71 | 0.0147 | Kuhn et al ( 2016) |
| Complement factor H‐related protein 1 | CFHR1 | 0.70 | 0.0166 | |
| Guanine deaminase | GDA | 0.78 | 0.0194 | |
| Kallikrein‐11 | KLK11 | 0.77 | 0.0200 | |
| Receptor‐type tyrosine‐protein phosphatase S | PTPRS | 0.77 | 0.0306 | Kuhn et al ( 2016) |
| Thyroxine‐binding globulin | SERPINA7 | 0.67 | 0.0470 | |
| Increase | ||||
| Chondroitin sulfate proteoglycan 4 | CSPG4 | 1.22 | 0.0191 | Sakry et al ( 2014) |
| Thymosin beta‐4 | TMSB4X | 1.26 | 0.0318 | |
| Programmed cell death protein 6 | PDCD6 | 2.00 | 0.0364 | |
| Cystatin‐M | CST6 | 1.20 | 0.0365 | |
| Dermcidin; Survival‐promoting peptide | DCD | 6.52 | 0.0467 | |
| Fatty acid‐binding protein, epidermal | FABP5 | 2.03 | 0.0469 | |
This table contains all proteins with a t‐test significance P‐value of < 0.05 (not corrected for multiple testing) and a change of the protein level of more than 20% compared to placebo‐treated controls. ADAM10 substrates are marked in bold.